Publications by authors named "Tara L Dimino"

Article Synopsis
  • The study compared the effectiveness of daprodustat, a new treatment for anemia in chronic kidney disease (CKD) patients on hemodialysis, with the standard treatment, epoetin alfa, in a noninferiority trial over 52 weeks.
  • Results showed that daprodustat was as effective as epoetin in improving hemoglobin levels, with 80% of daprodustat patients responding adequately, compared to 64% with epoetin.
  • Both treatments had similar rates of adverse events and impacts on blood pressure, while there was no significant difference in monthly intravenous iron use between the two groups.
View Article and Find Full Text PDF
Article Synopsis
  • Anaemia is a common issue for patients with chronic kidney disease (CKD), and it's crucial to evaluate new treatments like daprodustat compared to the existing drug, darbepoetin alfa.
  • The ASCEND-ND trial involved 3,872 adult participants across 39 countries, focusing on those with specific hemoglobin levels and assessing various health characteristics related to CKD.
  • The study aims to determine the effectiveness and safety of daprodustat in treating CKD-related anaemia in patients not on dialysis, providing important insights into managing this condition.
View Article and Find Full Text PDF
Article Synopsis
  • Daprodustat, a new oral treatment for anemia in chronic kidney disease (CKD) patients not on dialysis, was compared to the standard treatment darbepoetin alfa in a phase 3 clinical trial to evaluate effectiveness and safety.* -
  • The study included 3872 participants, revealing that daprodustat resulted in a slightly higher increase in hemoglobin levels (0.74 g/dL) compared to darbepoetin alfa (0.66 g/dL), meeting noninferiority benchmarks for effectiveness.* -
  • Cardiovascular safety outcomes showed daprodustat was also noninferior to darbepoetin alfa, with similar rates of major adverse cardiovascular events (19.5% vs. 19
View Article and Find Full Text PDF

This white paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of ventricular arrhythmias in early clinical pharmacology trials and their potential consequences for later clinical drug development. Ventricular arrhythmias are infrequent but potentially important medical events whose occurrence in early clinical pharmacology trials can dramatically increase safety concerns. Given the increasing concern with all potential safety signals and the resultant more extensive electrocardiographic monitoring of subjects participating in early phase trials, an important question must be addressed: Are relatively more frequent observations of ventricular arrhythmias related simply to more extensive monitoring, or are they genuinely related to the drug under development? The discussions in this paper provide current thinking and suggestions for addressing this question.

View Article and Find Full Text PDF

Management of Atrial Fibrillation. There are three fundamental approaches to the management of atrial fibrillation (AF): rate control, rhythm control, and anticoagulation. Selecting a course of treatment requires a thorough knowledge of these therapeutic alternatives.

View Article and Find Full Text PDF